Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR known ✓ | P02766 | 2/20 | 0.37 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.34 |
| ▸ | MMP1 known ✓ | P03956 | 2/20 | 0.34 |
| ▸ | MMP13 known ✓ | P45452 | 2/20 | 0.34 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.34 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.34 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.31 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 2/20 | 0.34 |
| ▸ | MMP14 | P50281 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819786 | 0.98 | MYC (0.44) | MYCTSHRSMN1; SMN2TTRPLCG1 | |
| Bromide SCHEMBL27524790 | 0.96 | MYC (0.43) | MYCTSHRSMN1; SMN2TTRPLCG1 | |
| SCHEMBL20854258 | 0.96 | MYC (0.43) | MYCTSHRSMN1; SMN2TTRPLCG1 | |
| SCHEMBL27912471 | 0.82 | PGAM1 (0.37) | MYCTSHRSMN1; SMN2TTRPLCG1 | |
| SCHEMBL313857 | 0.82 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRPLCG1 | |
| SCHEMBL30555661 | 0.82 | MYC (0.42) | MYCTSHRSMN1; SMN2TTRPLCG1 | |
| SCHEMBL1808793 | 0.81 | MYC (0.44) | MYCTSHRSMN1; SMN2TTRPLCG1 | |
| Hydrochloric Acid SCHEMBL28787033 | 0.81 | CYP2D6 (0.49) | MYCTSHRSMN1; SMN2TTRCYP1A2 | |
| Hydrochloric Acid SCHEMBL27375792 | 0.81 | CTSB (0.50) | MYCTSHRSMN1; SMN2TTRCTSB | |
| SCHEMBL4202392 | 0.80 | MYC (0.47) | MYCTSHRSMN1; SMN2TTRPLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1048513-A | The method of aluminium ring forming casting grooved roll | SHOUDU IRON AND STEEL CO (CN) | 1991-01-16 | — | — | CN | claimed |
| CN-105121444-B | Cyano ethyl Pyrazolopyridine ketone as the other than ring type of JANUS kinase inhibitors | 默沙东公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-104271552-B | Substituted heterocyclic acetamides as KAPPA Opioid Receptor (KOR) agonists | 雷迪博士实验室有限公司 | 2017-08-08 | — | — | CN | disclosed |
| US-20100113386-A1 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-7642250-B2 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1928467-A2 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038630-A2 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072825-A1 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
| CN-1048513-A | The method of aluminium ring forming casting grooved roll | SHOUDU IRON AND STEEL CO (CN) | 1991-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113386-A1 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | PPOX, PPIF, COX5A | TTR 521/4885CA2 4500/4885MMP1 3123/4885 |
| US-20070072825-A1 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | PPOX, PPIF, COX5A | TTR 521/4885CA2 4500/4885MMP1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.